Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Ticagrelor Fails Noninferiority to Prasugrel in TUXEDO-2
Added: 1 month ago Source:  Radcliffe CVRM
Written by Mirjam Boros, Radcliffe CardiologyThe optimal dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in high-risk patients with diabetes and multivessel disease remains a key clinical question. The TUXEDO-2 trial aimed to address this by directly comparing the efficacy and safety of ticagrelor versus prasugrel in this specific patient population… View more

Anticoagulation

Cardiovascular Kidney Metabolic
AHA 25: TUXEDO-2: Ticagrelor vs Prasugrel in Diabetic PCI
Author(s): Sripal Bangalore , Harriette Van Spall Added: 5 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) was joined by the TUXEDO-2 Principal Investigator, Dr Sripal Bangalore to present the findings of this late-breaking randomized trial comparing ticagrelor versus prasugrel in patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)… View more

Anticoagulation

Intervention
EuroPCR 24: The CAGEFREE II Trial
Author(s): Ling Tao Added: 1 year ago
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT… View more

Intervention
ACC 25: The Phase 3 REVERSE-IT Trial
Author(s): Deepak L Bhatt Added: 1 year ago
ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation
ACC 2025 Late-Breaking and Featured Science Collection
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 year ago
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the… View more

Intervention

Heart Failure
ESC Congress 2025 Releases its Late-Breaking Scientific Programme
Added: 9 months ago Source:  ESC Congress 2025 Scientific Programme
ESC Congress 2025 has released twenty-eight late-breaking trials and science sessions to be presented in August 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Late-Breaking Clinical Science: Inflammation and Immune Biomarkers in Cardiovascular Risk PredictionFriday 29th August, 08:15am – 09:45am (CEST… View more

Imaging & Diagnostics

Intervention
Lifestyle Modification after PCI
Author(s): Nicholas Nguyen , Katherine C Michelis Added: 1 year ago

Prevention & Chronic Conditions